CATALYST PHARMACEUTICALS, INC. — Form 8-K
Filed July 8, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 15/100
What the filing says
This 8-K filing from Catalyst Pharmaceuticals (filed 7/8/2026) references Items 5.02 and 5.07, indicating personnel/compensation changes and stockholder matters. However, the actual narrative disclosures are not present in the provided text—only metadata, file listings, and XBRL technical documents are shown. Specific counterparties, amounts, dates, and changes cannot be determined.
Why this rating
No substantive event details disclosed in provided text. Cannot assess materiality without actual narrative content describing the transaction or change.
Extracted items
- 5.02 exec change
- 5.07 shareholder vote
See more from July 8, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.